primary studies
published, non RCT
A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis - Not yet recruiting
- Year: 2026
- Date: 2006
- Author: Anagram Therapeutics, Inc.